Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging trial of IMO-8400 in moderate to severe plaque psoriasis
2013-000164-28Phase 2Completed
- Sponsor
- Aceragen, Inc.
- Start
- Mar 2013
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing IMO-8400 dose-ranging with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Mar 2013; status: completed.
02
Drugs
bazlitoran
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2013-000164-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000164-28.